Lumida
/CLDX
⌘K
Celldex Therapeutics Inc

Celldex Therapeutics Inc

CLDX
$36.90USD-3.15%-1.20 today

MARKET CAP

2.9B

P/E (TTM)

FWD P/E

DAY RANGE

$37 – $39

52W RANGE

$22
$45

AI Summary

Stalk
Sell NowMedium

CLDX has broken decisively below its key support around 38.8–39.4 in a Stage 3 distribution context, confirming supply dominance. Short-term price is extended below declining EMAs with no exhaustion visible, justifying Sell Now into the broken support–turned–resistance zone for continuation participation.

  • Phase 1 CDX-622 delivered dose-dependent, durable serum tryptase reductions.
  • Two Phase 3 barzolvolimab trial readouts in late 2026 could spark stock gains.
  • Profitability remains deeply negative, highlighting ongoing net losses.
Full analysis →
Insider Trades20 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jan 2, 2026BuyCLDXSamuel Bates MartinSVP AND CFO4,817$10.38$2.9B-18.25%+66.97%$50.0K+5.54%Sell Now
Dec 15, 2025BuyCLDXRonald PepinSR. VP & CBO19,333$5.47$2.9B-18.25%+66.97%$105.7K+130.09%Sell Now
Dec 4, 2025SellCLDXFreddy A. JimenezSVP & GENERAL COUNSEL4,166$29.09$2.9B-18.25%+66.97%$121.2K-11.92%Sell Now
Aug 13, 2025SellCLDXFreddy A. JimenezSVP & GENERAL COUNSEL771$24.77$2.9B-18.25%+66.97%$19.1K-1.08%Sell Now
Nov 11, 2024BuyCLDXAnthony S MarucciPRESIDENT & CEO11,500$26.82$2.9B-18.25%+66.97%$308.4K+39.95%Sell Now
Jun 14, 2024BuyCLDXSamuel Bates MartinSVP AND CFO37,341$21.78$2.9B-18.25%+66.97%$813.3K+1.85%Sell Now
Jun 14, 2024SellCLDXElizabeth CrowleySR. VP & CPDO60,000$22.62$2.9B-18.25%+66.97%$1.4M+0.00%Sell Now
Jun 11, 2024BuyCLDXDiane C. YoungSVP, CHIEF MEDICAL OFFICER15,000$2.71$2.9B-18.25%+66.97%$40.6K+709.22%Sell Now
Jun 7, 2024SellCLDXElizabeth CrowleySR. VP & CPDO30,000$22.38$2.9B-18.25%+66.97%$671.3K+0.00%Sell Now
Jun 7, 2024SellCLDXDiane C. YoungSVP, CHIEF MEDICAL OFFICER45,000$35.26$2.9B-18.25%+66.97%$1.6M-95.51%Sell Now
Jun 5, 2024BuyCLDXFreddy A. JimenezSVP & GENERAL COUNSEL9,540$10.38$2.9B-18.25%+66.97%$99.0K+21.50%Sell Now
Jun 3, 2024SellCLDXFreddy A. JimenezSVP & GENERAL COUNSEL16,012$21.99$2.9B-18.25%+66.97%$352.1K+0.00%Sell Now
Jun 3, 2024BuyCLDXMargo Heath-ChiozziSVP OF REGULATORY AFFAIRS123,027$21.35$2.9B-18.25%+66.97%$2.6M+5.46%Sell Now
Jun 3, 2024BuyCLDXRichard M. WrightSR. VP & CCO114,313$24.90$2.9B-18.25%+66.97%$2.8M+9.58%Sell Now
May 30, 2024SellCLDXSarah CavanaughSVP OF CORP AFFAIRS & ADMIN.41,706$19.76$2.9B-18.25%+66.97%$824.3K+0.00%Sell Now
May 30, 2024SellCLDXMargo Heath-ChiozziSVP OF REGULATORY AFFAIRS72,438$19.95$2.9B-18.25%+66.97%$1.4M-2.06%Sell Now
May 30, 2024SellCLDXSamuel Bates MartinSVP AND CFO60,000$24.19$2.9B-18.25%+66.97%$1.5M-5.69%Sell Now
May 30, 2024BuyCLDXElizabeth CrowleySR. VP & CPDO81,542$18.04$2.9B-18.25%+66.97%$1.5M+4.39%Sell Now
Feb 13, 2024BuyCLDXFreddy A. JimenezSVP & GENERAL COUNSEL24,166$3.86$2.9B-18.25%+66.97%$93.2K+314.58%Sell Now
Jan 2, 2024BuyCLDXSamuel Bates MartinSVP AND CFO10,750$2.78$2.9B-18.25%+66.97%$29.9K+44.10%Sell Now